Literature DB >> 8137340

Pharmacokinetics of alkylating agents.

M J Lind1, C Ardiet.   

Abstract

Alkylating agents have been used for over 30 years in the treatment of malignant disease. Because of their very reactive nature, studies of their intermediate metabolism have been difficult. However, this is now possible with modern analytical techniques. Further understanding of their metabolism and pharmacokinetics should lead to a more rational use in the clinic.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8137340

Source DB:  PubMed          Journal:  Cancer Surv        ISSN： 0261-2429


  5 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

2.  Lipid association increases the potency against primary medulloblastoma cells and systemic exposure of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats.

Authors:  C Bethune; A Blum; J R Geyer; J R Silber; R J Ho
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

3.  Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1.

Authors:  M Veyhl; K Wagner; C Volk; V Gorboulev; K Baumgarten; W M Weber; M Schaper; B Bertram; M Wiessler; H Koepsell
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

Review 4.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.